INTRODUCTION
A family of proteins isolated from snake venoms and leeches have been designated as disintegrins because they antagonize the activity of integrins [1] [2] [3] [4] . Binding to the glycoprotein Ilb-Illa on platelet membranes and inhibiting the binding of fibrinogen, they are potent platelet-aggregation inhibitors [5, 6] . A recent study [7] has demonstrated that triflavin (a member of the disintegrin family) binds to glycoprotein IIIa of activated platelets. The homologous and cysteine-rich snake venom proteins contain the Arg-Gly-Asp (RGD) sequence except for barbourin which has the Lys-Gly-Asp (KGD) sequence instead [8] . The RGD or KGD motif is involved in the binding of fibrinogen [9] , vitronectin [10] and fibronectin [11] to their receptors. Thus disintegrins are potential antithrombotic agents [12] able to interfere with the integrin-mediated events. For example, albolabrin and triflavin significantly inhibited the metastasis of B16 cells in mouse lungs [2, 6] , and it was reported that echistatin bound to the av-like integrin of osteoclasts and inhibited bone resorption by osteoclasts [13, 14] .
Echistatin al, a 49-amino acid disintegrin, was isolated from the venom of the sand viper Echis carinatus [15] , and the variant echistatin ac2, which is two residues shorter than al at the Cterminus, was found [1] . However, a platelet-aggregation inhibitor called carinatin was previously purified from the same viper venom [16] but its isoelectric point (4.8) was different from those reported for echistatin al and a2 (8.3 ). Therefore we residues 15, 21, 22 and 27, which are close to or within the RGD loop, rather than to the C-terminal variations after residue 46. Taking advantage of the presence ofmethionine residues flanking both sides of the ARGDDM motif in echistatin y, we deleted this hexapeptide by CNBr cleavage to produce des-(23-28)-echistatin y. The modified protein showed c.d. and fluorescent spectra grossly similar to the intact echistatin but its antiplatelet potency decreased more than 200-fold. We thus propose that a favourable conformation of the RGD region is responsible mainly for the high-affinity binding of echistatin to the platelet glycoprotein Ilb-Illa as shown previously for the binding of medium-size disintegrin.
speculated that echistatin variants other than a might exist in subspecies ofE. carinatus. Characterization ofvenom disintegrins from closely related species may promote a better understanding of the structure and function relationships of this family of proteins. In the present work we purified two novel variants of echistatin, which we named echistatin / and y, from the venom of Echis carinatus leakeyi, and determined their complete amino acid sequences, and also the disulphide bridge pattern of echistatin y. We also examined the effect of chemical modifications, such as oxidation of methionine residues flanking the RGD motif and removal of the RGD region by CNBr cleavage, on the antiplatelet activity of echistatin / and y. The significance of the presence of more than one disintegrin in one venom source and their structure-function relationships were investigated.
MATERIALS AND METHODS

Materials
E. carinatus leakeyi venom was purchased from Ventoxin Laboratories (Frederick, M.D., U.S.A.). Sephadex G-75 was from Pharmacia LKB. Trifluoroacetic acid (TFA), acetonitrile, and CNBr were purchased from Merck. Echistatin acl, ADP, apyrase, Trizma base, sodium citrate, N-acetyl-L-methionine, chloramine-T and Arg-C endopeptidase were obtained from Sigma. Phenyl isothiocyanate was purchased from Applied Biosystems. Endoproteinase Asp-N was from Boehringer, Mannheim, Germany. 4-NN-Dimethylaminoazobenzene-4'-iodoacetAbbreviations used: FITC, fluorescein isothiocyanate; PRP, platelet-rich plasma; PTH, phenylthiohydantoin; Rn, rhodostomin; SCM, Scarboxylmethyl; S-DABCAM, 4-dimethylaminoazobenzene-4'-carboxyamidomethyl; S-DABIA, 4-NN-dimethylaminoazobenzene-4'-iodoacetamino-2'-sulphonic acid; TFA, trifluoroacetic acid.
I To whom correspondence should be addressed. 513 amido-2'-sulphonic acid (S-DABIA) was a generous gift from Dr. J.-Y. Chang through Dr. C. S. Liu [17] . Des-(46-49)-echistatin y was synthesized on the basis of our sequence data by Dr. S. H. Wu and Dr. K. T. Wang using a peptide synthesizer (model 431A, Applied Biosystems).
Platelet-aggregation assay
Blood was collected from rabbits, Sprague-Dawley rats, guinea pigs or healthy human donors and mixed with 3.6% sodium citrate (9:1, v/v) before centrifugation at 200 g for 10 min at 25 'C, to prepare the platelet-rich plasma (PRP) [18] . Platelet aggregation was measured by the turbidimetric method [19] using an aggregometer (Jasco CAF-100 Ca2l analyser). The disintegrin samples were added to PRP 1 min before initiation of the aggregation by 10 ,M ADP. The IC50 value of a disintegrin, defined as the concentration to inhibit 50 % of the aggregation of PRP caused by 10,uM ADP, was determined from the dosedependence curve.
Purification of echistatin fl and y About 250 mg of the crude venom of E. carinatus leakeyi was dissolved in 1.5 ml of ammonium acetate, pH 6.8, and loaded on a Sephadex G-75 column. The column was eluted at a flow rate of 0.25 ml/min and fractions of 2.5 ml were collected. The fractions containing platelet-aggregation-inhibitory activity were pooled and purified by reversed-phase h.p.l.c. on a column (4.6 mm x 250 mm) of C18 gel (ODS-H; 5 gm; Chemcosorb Scientific Co., Osaka, Japan) using a gradient of solution B (0.07 % TFA in acetonitrile). The column was eluted at 1 ml/min under isocratic conditions (70% solution B) for the first 5 min followed by a 35 min linear gradient up to 27% solution B. Rabbit PRP was used to assay the aggregation inhibitor. The purity of echistatin , and y after h.p.l.c. was assessed by SDS/PAGE and automated N-terminal sequencing.
Protein and amino acid analysis Protein concentration was determined spectrophotometrically at 205 nm by using the following equation: concentration (mg/ml) = A205/3 1 [20] . The concentration of echistatin was also checked by amino acid analysis after vapour-phase hydrolysis at 158 'C for 30 min using 7 M HCI/10 % TFA/0.1 % phenol (by vol.) [21, 22] . Amino acids in the hydrolysate were derivatized to dimethyl aminoazobenzenesulphonyl amino acids before separation by reversed-phase h.p.l.c. [23] . The hydrolysate of purified egg white lysozyme were used as a reference.
Endoprotease and CNBr treatment and sequencing Echistatin (200 ,ug) was reduced in 100 ,ul of 0.2 M Tris/HCl (pH 8.0) containing 6 M guanidinium chloride and 20 mM dithiothreitol and incubated at 37 'C for 2 h. After the addition of 10 ,1 of 2M iodoacetic acid and incubation at 37 'C for 20 min in the dark, the S-carboxylmethylated (SCM-) proteins were isolated by reversed-phase h.p.l.c., and subjected to protein sequencing.
The SCM-echistatin (50 ,tg) was hydrolysed with 1 jug of Arg-C endopeptidase in 0. Figure 1 Gel-permeation chromatography of E. carinatus leakeyl venom
The crude venom (025 g in 1.5 ml of buffer) was applied to a column (1.5 cm x 95 cm) of Sephadex G-75 which was equilibrated and eluted with 50 mM ammonium acetate, pH 6.8, at 4 0C. The peak containing platelet-aggregation inhibitor is indicated by an arrow. acid derivatives were determined by an on-line h.p.l.c. system [24] .
C-terminal analysis
Carboxymethylated proteins (5 ,g) were digested with 0.5 ,ug of carboxypeptidase Y in 0.1 M ammonium acetate, pH 6.0, at room temperature [25] . After different lengths of time, samples were removed, 0.1 mM di-isopropyl fluorophosphate was added to stop the reaction, and the samples were dried in vacuum. The released residues were derivatized to dimethylaminoazobenzenesulphonyl amino acids and analysed [23] .
ldentfflcation of disulphide bridges in echistatin y Echistatin y (50,g) was digested with 1 ,g of endoproteinase Asp-N in 100 ,1 of 0.05 M sodium phosphate buffer, pH 8.0, for 16 h at 37 'C. The digested fragments were separated by reversedphase h.p.l.c. using a Chemosorb ODS-H column and a linear gradient from 5 to 300% acetonitrile in 0.07 % TFA. By automated protein sequencing we identified a fragment (R2, Figure  5a ) containing the polypeptides 1-25 and 30-49 linked by four disulphide bridges. The stepwise degraded PTH-amino acid derivatives of R2 at the fifth, seventh and eighth cycle were recovered, and each was reduced with 0.5 nmol of dithiothreitol in 20,tl of 0.1 M NH4HCO3 buffer (pH 8.5) for 1 h at room temperature, and then 10 nmol of S-DABIA [17] in 2 ,ul of water was added. The mixture was incubated for another hour at room temperature in the dark and 20 ,ul of 1 % TFA were added before purification by reversed-phase h.p.l.c. The synthetic 4-dimethylaminoazobenzene-4'-carboxyamidomethyl derivative of PTHcysteine (S-DABCAM PTH-Cys) was prepared and used as the h.p.l.c. standard [26] .
Oxidation of methionine residues
Echistatin ft and y (20,g) were dissolved in 200,ul of 0.1 M borate buffer, pH 8.5, and oxidized with up to 160 ,uM chloramine-T [27] . After incubation for 30 min at 25 'C, the excess oxidant was scavenged by 200 #M N-acetylmethionine.
Aggregation-inhibition activity of the modified proteins was studied using the rabbit and human PRP.
C.d. spectroscopy C.d. studies were performed with a Jasco J-720 spectropolarimeter under nitrogen gas. The spectra were measured in a thermostatically controlled 1 mm quartz cuvette at a peptide concentration of 50 ,M in water (pH -5) with 0.5 nm band width, 0.2 nm step resolution and a 2.0 s time constant. For each spectrum, three scans were averaged, corrected for solvent contributions and analysed by non-linear regression.
Fluorescein isothiocyanate (FITC) conjugation of rhodostomin (Rn)
Rn was purified from Calloselasma rhodostoma venom (Latoxan) as described previously [28] . FITC solution freshly prepared before the conjugation reaction (10 ,l) was added to Rn stock solution (6-8 mg/ml in 0.1 M NaHCO3) and incubated at room temperature for 1 h with continuous vortexing. The freshly prepared 1.5 M hydroxylamine (pH 8.0-8.5) was then added to stop the reaction, and a Sephadex G-I0 column equilibrated with PBS was used to isolate FITC-conjugated rhodostomin (FITC-Rn) from the mixture. The antiplatelet activity of Rn was not affected by the labelling reaction.
Flow-cytometry measurement
Venous blood from an adult donor who had taken no medicine for 2 weeks was collected and centrifuged to obtain PRP and its platelet count was adjusted to 2 x 108 platelets/ml with saline. PRP (20 ,ul) and FITC-Rn (2 ,ul) were added to polypropylene tubes containing 178 ,1 of Tyrode solution (0.4 mM NaH2PO4, 136.9 mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO3, 0.5 mM CaCl2 and 3.5 mg/ml BSA, pH 7.4) and mixed. After 30 min at room temperature, the mixture was brought to 2 ml with Tyrode solution and immediately subjected to fluorescent flow-cytometer analysis. For displacement experiments, native or des-(23-28)-echistatin y was added 3 min before the addition of FITC-Rn. Non-specific binding of FITC-Rn was determined using EDTA/ Tyrode solution (5 mM EDTA and no Ca2l) instead of Tyrode solution. A Coulter Epics Profile flow cytometer (Coulter Electronics) was used to analyse the fluorescence histograms. Excitation and emission wavelengths were at 488 nm and 525 nm respectively. Each histogram was generated by quantifying the fluorescence intensity of 50 000 platelets, and the peak height was indicative of the number of platelets with a given intensity.
RESULTS
Purification of echistatin f, and y Echistatin variants were purified to homogeneity from the venom of E. carinatus leakeyi in two steps: first gel-filtration chromatography (Figure 1) , then reversed-phase h.p.l.c. (Figure 2 ). Two active inhibitors were eluted at 13 and 23 % acetonitrile and designated echistatin 3 and y respectively. Their respective yields were about 0.5 and 1 % (w/w) of the venom. Echistatin a was not found in this venom.
Amino acid sequences
The amino acid sequences of echistatin , and y were determined by automated sequencing of their SCM derivatives up to the 46th residue, as well as the peptides derived by CNBr cleavage and endoproteinase Arg-C digestion. The complete amino acid sequences of four echistatin variants are listed for comparison (Figure 3 ). Their C-terminal sequences were also confirmed by ArgC-B1 Species-specificity of the antiplatelet activities of echistatin variants
We have compared the dose-dependent inhibitory effects of the echistatin variants on PRP of various species. IC50 values were calculated from the dose-dependence curves (Figure 4) . Echistatin was more potent than ac or y toward human PRP, but for inhibition of rabbit PRP, echistatin y was the most potent and the IC50 values of echistatin , and ax were 2-3-fold higher than that of echistatin y (Figure 4) . In general, human and guinea-pig PRP were more sensitive to echistatins than rabbit and rat PRP. Both echistatins ot and showed prominent species specificity, e.g. echistatin ,B had an IC50 for rabbit PRP 14-fold and for rat PRP about 200-fold higher than that for human PRP. In contrast, echistatin y was less discriminating among platelets of different species tested.
The effects of removal of the C-terminal highly variable residues of echistatin y were studied using a synthetic truncated form, des-(46-49)-echistatin y, which could fold properly as shown by its c.d. spectrum and which, like the native form, was a very potent inhibitor of rabbit platelet aggregation [29] . We also found that des-(46-49)-echistatin y retained the same antiplatelet potency as native echistatin y toward both human and rabbit PRP.
Identification of disulphide bridges in echistatin y
There are four disulphide bridges in echistatin a and only two of them (C2-Cll and C20-C39) were determined by early n.m.r. study [30] . Here, we used endopeptidase Asp-N and S-DABIA to determine the other two pairs of disulphides involving Cys residues 7, 8, 32 and 37 in echistatin y. A polypeptide (R2) containing four disulphides bridges was obtained by proteolysis ( Figure 5a ). The deduced sequence of R2 is shown in Figure 5 (b). This peptide (about 0.5 nmol) was subjected to automated sequencing, and its PTH-amino acid derivatives from steps 5, 7 and 8 were recovered and further reduced by dithiothreitol. Their thiol groups were then modified with S-DABIA and the reddish products were analysed quantitatively by h.p.l.c. with the absorbance monitored at 436 nm. It is expected that if Cys-7-Cys32 and Cys8-Cys37 are present, both steps 7 and 8 of the R2 sequencing would produce comparable PTH-cystine. Alternatively, if it were Cys7-Cys37 and Cys8-Cys32, step Figure 6 Effect of methionine oxidation on the activities and specfflcities of echistatin /1 and y In the present study, the methionine residues of echistatin , and y, being several residues away from the RGD motif, were oxidized to methionine sulphoxides with chloramine-T. Figure 7 shows the time-dependent and dose-dependent effect of meth- 
DISCUSSION
The heterogeneity and different anticoagulation activities of E. carinatus venoms from different geographic regions have been reported [30] . In the present paper, we have isolated two novel variants of echistatin from the venom of E. carinatus leakeyi. The presence of disintegrin isoforms in the venoms of E. carinatus subspecies reflects the evolution of these species in different geographic environments. Echistatin ft and y have 50 and 49 residues respectively including eight cysteines; their protein sequences were respectively 88 and 84% identical with that of echistatin aAl. Echistatin y has acidic or neutral residues at positions 15, 21 thus has a pl value of 4.5, similar to that of carinatin [16] . Echistatin f (pl 9.2) differs from al (pl 8.3) by seven residues. In previous mutagenesis studies of kistrin, a medium-size disintegrin, two mutants F38A and Q60A could not be expressed, presumably because of a folding problem [38] . Residues 38 and 60 of kistrin correspond to Phe"3 and Lys35 respectively in echistatins. These two residues are conserved in all the echistatins ( Figure 3 ) and many other disintegrins [1] [2] [3] [4] . Whether they are important for the folding of small disintegrins remains to be ascertained.
Interestingly, the present study showed that platelets from different species have different sensitivities to the echistatin isoforms. Within human PRP the inhibition follows the order echistatin > a > 'y, and with rabbit PRP the potency order is y > > >a (Figure 4) . It has been reported [32, 33] that some monoclonal antibodies against human platelet glycoprotein IlIbIlla failed to react with rabbit platelet receptors, and it was recently shown in studies performed with whole blood that rat and hamster platelets were about 100-fold less sensitive than human, monkey and guinea-pig platelets to echistatin a and RGDW [34] . Our study has highlighted the evolution of snake venom disintegrins with respect to platelets of different origin. We and rabbit PRP. Our results indicate that this truncation did not affect the antiplatelet potency of echistatin y for either human or rabbit PRP. Therefore we conclude that the difference in speciesdependent specificities of echistatins , and y is not due to variations in their C-terminal regions, but is probably related to differences in residues 15, 21, 22 and 27 (Figure 3) , which are close to [30, 36] or within the RGD loop. Echistatins a and apparently have similar species specificity and their residues 15, 21 and 22 are identical (Figure 3) .
Previous studies have noted that large hydrophobic side chains in the X position of the RGDX sequence are optimal for highaffinity interactions with human platelet glycoprotein Ib-Illa and possibly other integrins [11, [37] [38] [39] . Thus the higher activity of echistatin , compared with a and y in inhibiting aggregation of human platelets (Figure 4a) is at least partly due to the replacement of Asp27 with Asn ( Figure 3) . However, this cannot be the complete explanation for the less discriminating activity of echistatin y as echistatin a also has Asp27 but hardly inhibits rabbit platelet aggregation at all (Figure 4b) .
Residue Met28, which is conserved in all the echistatin variants, is better than its sulphoxide at inhibiting aggregation of both human and rabbit platelets as suggested by a 2. 1-fold inactivation of echistatin /8 after the chloramine-T treatment ( Figure 8) ; oxidation of Met22 in addition to Met28 in echistatin y resulted in a greater reduction (3.6-fold) of its inhibitory activity toward rabbit PRP which is more pronounced than for human PRP (2.5-fold). Thus Met22 of echistatin y is probably involved in the selectively in rabbit platelets (Figure 4) but not in human platelets.
On the other hand, Lys21 and Arg22 of echistatin , and a probably aid the recognition of human platelets because it was shown by a mutagenesis study of Arg46 in kistrin (corresponding to Lys2' in echistatin ,3) that basic charge at this region was important for the binding of kistrin to human glycoprotein Ilb-Illa [40] .
There is no direct evidence for the involvement of Glu15 of echistatin y in the species-dependent platelet sensitivity. However, of all the distintegrins known, only trigramin a and echistatin y contain the IEE or LEE sequence at residues 14-16, other disintegrins containing basic residues at the corresponding region. Trigramine a has been shown to have similar activity on rabbit and human platelets (IC5. values are 3.1 and 3.4,ug/ml respectively) (T. F. Huang, unpublished work). In contrast, echistatin a/, and trigramin /3/y have basic substitutions at positions 15 and 22 (echistatin numbering) and apparently inhibit human and guinea-pig PRP more selectively (Figure 4 ). We therefore conclude that the charge and hydrophobicity ofresidues 15, 21, 22 and 27 of each echistatin variant determine its speciesdependent platelet sensitivity.
Recently, the disulphide links in echistatin al were identified by direct chemical analysis [41] and a simulated annealing analysis of the n.m.r. data [42] . Our data suggest that echistatin y has the same disulphide pattern as echistatin a, i.e. Cys2-Cys"1, CyS7_CyS32, Cys8-Cys37 and Cys20-Cys39. Only Cys20-Cys39 and Cys7-Cys32 are highly conserved among all snake venom disintegrins. The disulphide Cys2_Cys11 is probably also important since both Cys2 and Cys1' are conserved (although the linkages in which they are involved may vary among different disintegrins) [41] . The importance ofCys8-Cys37 ofechistatin remains obscure; Cys37 is absent from all medium-size disintegrins.
The great reduction (_ 102-103) in platelet-aggregationinhibitory potency of des-(23-28)-echistatin y, i.e. after ARGDDM deletion, suggests the importance of this region for its antiplatelet activity, although other sites in echistatin may also be weakly or indirectly involved in the receptor recognition. For example, the proline-rich C-terminal residues 40-49 in echistatin a have been shown to activate glycoprotein Ilb-Illa for binding to fibrinogen and collagen [43] and have sequences homologous to the human vWF segment 1726-1764 [44] . Moreover, the results of a recent n.m.r. study of other disintegrins suggest that residues corresponding to 42 and 43 of echistatin are probably located close to the RGD motif [36] . However, it required millimolar concentrations of the C-terminal region alone, as suggested by the IC50 of the synthetic echistatin a-(40-49)-peptide, for antagonization of GPIIb-IIIa binding to the immobilized echistatin [43] . In the flow-cytometry assay (Figure 6 ), the lack of activity of 21,M des-(23-28)-echistatin in displacing FITC-Rn also suggests that the contribution of non-RGD domains in echistatin to the binding is relatively minor (less than I % that of the RGD loop). This conclusion is in accord with the results of site-directed mutagenesis studies on a medium-size disintegrin, kistrin [40] .
It has been reported that nanomolar concentrations of echistatin a inhibited the attachment of cancer cells to vitronectin and fibronectin [8] . Previous studies [11, [37] [38] [39] have shown that various RGD-dependent integrins (e.g. orr/3 and a5/31) recognize differences in the conformation and environment of the RGD motifs of adhesion inhibitors. How the unique N21M22 sequence N-terminal to the ARGD tetrapeptide in echistatin y (corresponding to K21R22 in echistatin a) affects its integrin specificity remains to be studied.
